In value terms, M&A activity in China decreased by 76% in Q2 2023 compared with the previous quarter’s total of $1.1bn and fell by 64% as compared to Q2 2022. Related deal volume decreased by 28% in Q2 2023 versus the previous quarter and was 271% higher than in Q2 2022.

The top-ranked legal advisorss supporting these M&A deals in China Q2 2023 were Beijing Deheng; DeHeng Law Offices; Dorsey & Whitney with 1, 1, 1 deals respectively.

For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.

This content was updated on 18 July 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.